Jin Honglin, Qian Yuan, Dai Yanfeng, Qiao Sha, Huang Chuan, Lu Lisen, Luo Qingming, Chen Jing, Zhang Zhihong
Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan 430074, China;; MoE Key Laboratory for Biomedical Photonics, Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan 430074, China;; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan 430022, China.
Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan 430074, China;; MoE Key Laboratory for Biomedical Photonics, Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan 430074, China.
Theranostics. 2016 Sep 2;6(11):2000-2014. doi: 10.7150/thno.15102. eCollection 2016.
Dendritic cell (DC) migration to the lymph node is a key component of DC-based immunotherapy. However, the DC homing rate to the lymphoid tissues is poor, thus hindering the DC-mediated activation of antigen-specific T cells. Here, we developed a system using fluorescent magnetic nanoparticles (α-AP-fmNPs; loaded with antigen peptide, iron oxide nanoparticles, and indocyanine green) in combination with magnetic pull force (MPF) to successfully manipulate DC migration and . α-AP-fmNPs endowed DCs with MPF-responsiveness, antigen presentation, and simultaneous optical and magnetic resonance imaging detectability. We showed for the first time that α-AP-fmNP-loaded DCs were sensitive to MPF, and their migration efficiency could be dramatically improved both and through MPF treatment. Due to the enhanced migration of DCs, MPF treatment significantly augmented antitumor efficacy of the nanoparticle-loaded DCs. Therefore, we have developed a biocompatible approach with which to improve the homing efficiency of DCs and subsequent anti-tumor efficacy, and track their migration by multi-modality imaging, with great potential applications for DC-based cancer immunotherapy.
树突状细胞（DC）迁移至淋巴结是基于DC的免疫疗法的关键组成部分。然而，DC归巢至淋巴组织的比率较低，从而阻碍了DC介导的抗原特异性T细胞的激活。在此，我们开发了一种系统，该系统使用荧光磁性纳米颗粒（α-AP-fmNPs；负载有抗原肽、氧化铁纳米颗粒和吲哚菁绿）并结合磁力牵引（MPF），以成功操控DC迁移。α-AP-fmNPs赋予DC对MPF的响应性、抗原呈递能力以及同时具备光学和磁共振成像检测能力。我们首次表明，负载α-AP-fmNP的DC对MPF敏感，并且通过MPF处理，其迁移效率在体内和体外均可显著提高。由于DC迁移增强，MPF处理显著增强了负载纳米颗粒的DC的抗肿瘤功效。因此，我们开发了一种生物相容性方法，可提高DC的归巢效率及后续抗肿瘤功效，并通过多模态成像追踪其迁移，在基于DC的癌症免疫疗法中具有巨大的潜在应用价值。
